Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen - Wikidata - awgldk - TriplyDB

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

http://www.wikidata.org/entity/Q35328111

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Current Immunotherapies for Sarcoma: Clinical Trials and Rationale PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Current clinical trials testing the combination of immunotherapy with radiotherapy.Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.The role of PD-L1 in the radiation response and clinical outcome for bladder cancer.Patient-Derived Xenografts as a Model System for Radiation Research Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.Reprogramming the immunological microenvironment through radiation and targeting Axl.Radiotherapy and immune checkpoint blockades: a snapshot in 2016.Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports.Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis Immune checkpoint inhibitors: a new frontier in bladder cancer.Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection.Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Combining radiotherapy with immunotherapy: the past, the present and the future.Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.Irradiation and immunotherapy: From concept to the clinic.Immunotherapy and radiation in glioblastoma.Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer.Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?Emerging targets for radioprotection and radiosensitization in radiotherapy.

P2860

Q26738443-0FC9B106-5B87-4F95-B137-B7702A0AF4DC Q26742107-65D19841-148C-41E0-9EE4-5AC86632DD06 Q26744490-524EC174-1A68-4A89-A60E-5239A9297233 Q26779221-6C40A36B-240B-4F46-A1CB-57E90145C9EA Q28066199-9A02E6F3-D936-4418-8BAA-EFFFBD22DDB6 Q28067036-5BA97112-4CE1-4E26-8160-AFC8E740CCAB Q28075712-7E5D7EFF-23CA-4E59-A6C0-FAD90E406812 Q30356447-C19D27AF-4A22-4122-8417-4E52B2693F2A Q33645624-FD2CEE1B-47C6-45A2-B3F6-D2B2EBEB420E Q36046884-50921641-9F77-4B70-A935-C01CF11056B9 Q36416387-AF856A98-E564-4BAD-8965-B77EBA5D525D Q36500650-915120BD-26E3-4A71-9110-73E7F609434F Q36592961-ED0E3629-77DD-431D-8866-FADD8FA44A54 Q36746004-C1319EC8-E317-4588-BD93-083DDD4749E8 Q37053820-E9FFC1E9-EA00-43E0-9439-A7195B2054D3 Q37118895-52DC87A3-14DB-4BCE-94F8-F9B79C373281 Q37178662-ADC69763-31E7-4701-AEBB-7C51225D9C3D Q37518395-60D230CA-0398-4CE7-8724-5ECF755E1B84 Q37541688-5D6DFB51-B919-424D-8636-3664CB6D8EA4 Q37551762-ADF63A24-E198-4D22-9894-537D50E6BF35 Q37582620-08AB872C-E853-4739-B559-3A376990E061 Q37589407-FFBCA643-5642-4F39-89F3-3AF41F0DD4DA Q37615827-0FDD9CB7-1E6D-4D7C-A4FE-EB952265664D Q37656305-34955471-7063-4A85-BD58-CD4DDF6F3B19 Q37714274-0039392C-4519-4A30-8BD7-1174B0845BC5 Q37729387-8449DE05-ECB7-4594-A69F-E5F799020246 Q38612706-755107B7-A5EA-4086-A3CD-DF9A0753B8F8 Q38621228-74B61E1B-8A6C-4BBE-9080-D6101E26D5ED Q38632924-8FF220C2-2502-42B7-8C91-E1A79CEA5070 Q38635512-E7B025EC-3CC7-48EC-80FB-0CE43D6D8178 Q38645128-C2709687-E720-4509-8A2D-24A34CA731CF Q38679418-E2A7BC22-EEE6-41E2-B124-88E6C0A98E8F Q38746437-AB5F4E3F-3022-4652-A6F2-F646DF999A95 Q38749802-5EDB636C-9FC3-486B-A7AE-44EA87B1BF22 Q38752191-1B874CF5-1641-421D-B508-F2748ED9A8EB Q38760078-3571EFDB-C309-4523-8974-B4454FB72E4D Q38760780-CB6402F0-A9E0-42B5-AE25-BCE9A9825AE6 Q38771934-1BC0B7D0-3AFE-4D35-B208-F6713E400E3E Q38828265-C8536DD3-771C-46EB-9298-0CA862F16C50 Q38869603-3CD4AED7-F776-4B48-B315-6C4E366ED59D

P2860

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

http://www.wikidata.org/entity/Q35328111

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Stereotactic Radiation Therapy ...... -Presentation of Tumor Antigen

@ast

Stereotactic Radiation Therapy ...... -Presentation of Tumor Antigen

@en

type

label

Stereotactic Radiation Therapy ...... -Presentation of Tumor Antigen

@ast

Stereotactic Radiation Therapy ...... -Presentation of Tumor Antigen

@en

prefLabel

Stereotactic Radiation Therapy ...... -Presentation of Tumor Antigen

@ast

Stereotactic Radiation Therapy ...... -Presentation of Tumor Antigen

@en

P1433

Q35328111-D5A71ADE-D063-4EE3-A050-60289A325A6B

P1476

Q35328111-47F357DE-E5F1-41B5-92FD-29BD1BFAFAD7

P2093

Q35328111-03E15302-3D8E-4725-AD05-0766DA3A2094

Q35328111-1CE5FCD6-37D2-4C39-8A58-458BD90C3A0C

Q35328111-22493C0F-85C0-4818-9644-F2C3E43C49AB

Q35328111-2A8032EA-198C-476A-9118-479D4D15E74A

Q35328111-2CD7A724-5CF1-49CC-BF26-4B738091C7E5

Q35328111-30F6AA24-8DD5-4FC9-A8AA-8098E25A23C3

Q35328111-C1A961EE-A0B9-421F-9790-EFAAA80F986B

Q35328111-EF9CFDE9-6247-4FE2-B407-57639D41F65B

P2860

Q35328111-086DCA73-D16C-4A42-92AD-8E6AC94A899D

Q35328111-129C4568-433C-4FF1-AF84-048AD109D3FC

Q35328111-1FBAA93B-F74D-4ABF-A1AC-5E356D207945

Q35328111-21194315-4199-4625-BAFB-007F862B2582

Q35328111-2613A45A-42A1-42BF-9C2D-DA0ABC8F7886

Q35328111-26BAB509-5FD6-46DB-A0D6-63A219EDE06B

Q35328111-2BF29176-C887-4B8F-82B0-A623A54B4644

Q35328111-3165C165-3905-4F48-BA46-1A86D491E9C0

Q35328111-374E6808-E40E-4B3D-A1EB-FD9D90F997C7

Q35328111-39FAD5BE-2688-44AB-BF4C-58E9F82021BF

P304

Q35328111-A1ED3923-FB05-4F89-B185-CB1415F3B060

P31

Q35328111-C7268979-B529-42D5-B06A-3B24FE57C709

P356

Q35328111-F00C7B23-2A44-4CE8-8E39-AEF7642272A6

P433

Q35328111-8A104331-0CE4-493C-8D29-C976CF37D384

P478

Q35328111-558B66A2-B237-4097-AD15-09128756A0AF

P577

Q35328111-1AFA2981-2058-48C1-BD29-B3D27A3258DD

P698

Q35328111-89363633-1B1A-48CC-BEA7-D421D6DE0778

P921

Q35328111-1000D076-1ABB-4BC3-89EE-C11EAD05F275

P932

Q35328111-EA82A680-0B6B-450D-884E-DCF131C99387

P356

2326-6066.CIR-14-0196

P1433

Cancer immunology research

P1476

Stereotactic Radiation Therapy ...... -Presentation of Tumor Antigen

@en

P2093

Andrew B Sharabi

http://www.w3.org/2001/XMLSchema#string

Brian J Francica

http://www.w3.org/2001/XMLSchema#string

Charles G Drake

http://www.w3.org/2001/XMLSchema#string

Christina M Kochel

http://www.w3.org/2001/XMLSchema#string

Christopher J Nirschl

http://www.w3.org/2001/XMLSchema#string

Esteban Velarde

http://www.w3.org/2001/XMLSchema#string

Theodore L Deweese

http://www.w3.org/2001/XMLSchema#string

Thomas R Nirschl

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of the ATM kinase by ionizing radiation and phosphorylation of p53

Combining radiotherapy and cancer immunotherapy: a paradigm shift

Nivolumab plus ipilimumab in advanced melanoma.

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity

Immunologic correlates of the abscopal effect in a patient with melanoma

P304

345-355

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-14-0196

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25527358

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

4390444

http://www.w3.org/2001/XMLSchema#string